- Application under evaluation
- CHMP opinion
- European Commission decision
Overview
The marketing authorisation for Livensa has been withdrawn at the request of the marketing authorisation holder.
Livensa : EPAR - Summary for the public
English (EN) (168.44 KB - PDF)
български (BG) (298.14 KB - PDF)
español (ES) (169.76 KB - PDF)
čeština (CS) (273.22 KB - PDF)
dansk (DA) (230.75 KB - PDF)
Deutsch (DE) (231.16 KB - PDF)
eesti keel (ET) (229.87 KB - PDF)
ελληνικά (EL) (303.78 KB - PDF)
français (FR) (230.16 KB - PDF)
italiano (IT) (231.29 KB - PDF)
latviešu valoda (LV) (275.77 KB - PDF)
lietuvių kalba (LT) (195.76 KB - PDF)
magyar (HU) (267.45 KB - PDF)
Malti (MT) (211.01 KB - PDF)
Nederlands (NL) (229.84 KB - PDF)
polski (PL) (272.31 KB - PDF)
português (PT) (169.55 KB - PDF)
română (RO) (254.75 KB - PDF)
slovenčina (SK) (270.77 KB - PDF)
slovenščina (SL) (266.51 KB - PDF)
Suomi (FI) (244.98 KB - PDF)
svenska (SV) (230.23 KB - PDF)
Product information
Livensa : EPAR - Product Information
English (EN) (377.06 KB - PDF)
български (BG) (779.65 KB - PDF)
español (ES) (373.47 KB - PDF)
čeština (CS) (628.12 KB - PDF)
dansk (DA) (376.27 KB - PDF)
Deutsch (DE) (332.54 KB - PDF)
eesti keel (ET) (378.18 KB - PDF)
ελληνικά (EL) (812.94 KB - PDF)
français (FR) (383.13 KB - PDF)
íslenska (IS) (241.65 KB - PDF)
italiano (IT) (323.51 KB - PDF)
latviešu valoda (LV) (703.94 KB - PDF)
lietuvių kalba (LT) (463.76 KB - PDF)
magyar (HU) (610.27 KB - PDF)
Malti (MT) (665.37 KB - PDF)
Nederlands (NL) (382.03 KB - PDF)
norsk (NO) (241.85 KB - PDF)
polski (PL) (620.13 KB - PDF)
português (PT) (323.31 KB - PDF)
română (RO) (476.65 KB - PDF)
slovenčina (SK) (630.59 KB - PDF)
slovenščina (SL) (606.4 KB - PDF)
Suomi (FI) (378.28 KB - PDF)
svenska (SV) (378.43 KB - PDF)
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Livensa : EPAR - All Authorised presentations
English (EN) (122.11 KB - PDF)
български (BG) (172.13 KB - PDF)
español (ES) (120.96 KB - PDF)
čeština (CS) (156.51 KB - PDF)
dansk (DA) (115.87 KB - PDF)
Deutsch (DE) (115.58 KB - PDF)
eesti keel (ET) (115.96 KB - PDF)
ελληνικά (EL) (165.22 KB - PDF)
français (FR) (115.46 KB - PDF)
íslenska (IS) (26.59 KB - PDF)
italiano (IT) (115.34 KB - PDF)
latviešu valoda (LV) (162.55 KB - PDF)
lietuvių kalba (LT) (156.11 KB - PDF)
magyar (HU) (136.2 KB - PDF)
Malti (MT) (168.13 KB - PDF)
Nederlands (NL) (116.09 KB - PDF)
norsk (NO) (28.3 KB - PDF)
polski (PL) (139.63 KB - PDF)
português (PT) (115.26 KB - PDF)
română (RO) (154.64 KB - PDF)
slovenčina (SK) (153.87 KB - PDF)
slovenščina (SL) (139.83 KB - PDF)
Suomi (FI) (115.23 KB - PDF)
svenska (SV) (115.51 KB - PDF)
Product details
- Name of medicine
- Livensa
- Active substance
- Testosterone
- International non-proprietary name (INN) or common name
- testosterone
- Therapeutic area (MeSH)
- Sexual Dysfunctions, Psychological
- Anatomical therapeutic chemical (ATC) code
- G03BA03
Pharmacotherapeutic group
Sex hormones and modulators of the genital systemTherapeutic indication
Livensa is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy.
Authorisation details
- EMA product number
- EMEA/H/C/000630
- Marketing authorisation holder
- Warner Chilcott Deutschland GmbH
Warner Chilcott Deutschland GmbH
Dr.-Otto-Röhm-Strasse 2-4
D-64331 Weiterstadt
Germany - Marketing authorisation issued
- 28/07/2006
- Revision
- 6
Assessment history
Livensa : EPAR - Procedural steps taken and scientific information after authorisation
English (EN) (178.49 KB - PDF)
More information on Livensa
Public statement on Livensa (testosterone): withdrawal of the marketing authorisation in the European Union
English (EN) (107.69 KB - PDF)